Breaking News Instant updates and real-time market news.

IMMU

Immunomedics

$18.11

0.96 (5.60%)

06:56
01/24/18
01/24
06:56
01/24/18
06:56

Immunomedics price target raised to $22 from $16 at Jefferies

Jefferies analyst Matthew Andrews raised his price target for Immunomedics to $22 saying his analysis suggests a 98% FDA approval probability of IMMU-132. The shares could be worth $27 on approval, Andrews tells investors in a research note. He keeps a Buy rating on Immunomedics.

IMMU Immunomedics
$18.11

0.96 (5.60%)

12/06/17
JEFF
12/06/17
NO CHANGE
JEFF
Buy
Immunomedics breast cancer data continue to look 'very solid,' says Jefferies
Jefferies analyst Matthew Andrews says the totality of Immunomedics' Phase II breast cancer data for IMMU-132 "continue to look very solid." Importantly, there was no clinically meaningful decrease in objective response rate per blinded central review, Andrews tells investors in a research note after the company announced updated results. The analyst reiterates a Buy rating and believes the data is sufficient to support FDA accelerated approval.
11/14/17
COWN
11/14/17
NO CHANGE
Target $15
COWN
Outperform
Immunomedics drug survival rate disappointing but approval likely, says Cowen
Cowen analyst Phil Nadeau said the overall survival rate for Immunomedics' IMMU-132 showed a decrease, which was disappointing, but the response rate is still well above the current standard of care. As a result, the analyst believes it still appears likely to get accelerated FDA approval. Nadeau reiterated his Outperform rating and $15 price target on Immunomedics shares.
11/14/17
JEFF
11/14/17
NO CHANGE
Target $16
JEFF
Buy
Jefferies disagrees with yesterday's selloff in Immunomedics
Immunomedics closed down 19% yesterday largely due to interim overall survival data for IMMU-132 and concerns the FDA will require Phase III overall survival data for approval, Jefferies analyst Matthew Andrews tells investors in a research note. The analyst disagrees, and keeps a Buy rating on the shares with a $16 price target. The progression-free survival is the Phase III Special Protocol Assessment's primary endpoint, while the overall survival data may ultimately be confounded by patients' use of other drugs after progression, Andrews tells investors in a research note. Precedent for objective response rate/duration of response exists with FDA breakthrough therapy approvals of 12 solid tumor drugs, some with less robust efficacy than IMMU-132, the analyst adds.
11/13/17
WELS
11/13/17
NO CHANGE
Target $14
WELS
Outperform
Immunomedics weakness a buying opportunity, says Wells Fargo
Wells Fargo analyst Jim Birchenough said weakness in Immunomedics is a buying opportunity following review of SABCS abstract data for IIMU132 in TNBC saying he believes the data supports accelerated approval. Birchenough rates Immunomedics an Outperform with a $14 price target.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.